Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Uroplakin II antibody IVD, 7/13:104

Biocare Medical’s uroplakin II mouse monoclonal antibody (IVD) is now available. Studies have shown UP II mRNA to be expressed in bladder cancer tissues and the peripheral blood of patients with primary and metastatic urothelial carcinoma. Pathologists have used uroplakin III [AU1] to establish urothelial origin of the bladder; however, use of UP III is limited owing to its poor sensitivity. UP II was found to have 79 percent (44/56) sensitivity for bladder urothelial carcinoma compared with 34 percent (19/56)

MRSA/SA test, 7/13:104

Cepheid has received FDA clearance to market its Xpert MRSA/SA blood culture test, which runs on its GeneXpert system, for the detection of methicillin-resistant Staphylococcus aureus and S. aureus in blood culture bottles showing gram-positive cocci in clusters in about one hour. Cepheid’s updated Xpert MRSA/SA BC test processes positive blood culture specimens to determine whether a patient’s blood is infected with MRSA or SA, which are frequent causes of sepsis in hospitalized patients. “Having the capability to differentiate MRSA, S.

CAP 15189 renewal for National Jewish Health, 7/13:104

The College of American Pathologists has renewed CAP 15189 Accreditation for National Jewish Health Advanced Diagnostic Laboratories. The accreditation, based on standard 15189 for laboratory technical competence and continual quality management, is administered by the International Organization for Standardization and seeks to improve patient safety and reduce risk, by outlining standards for quality and competence in medical laboratories. CAP 15189 is a voluntary, non-regulatory accreditation to the ISO 15189:2007 standard as published by ISO. The program complements CAP accreditation and

Remote microscopy telepathology tool, 7/13:104

MikroScan Technologies’ Live-Q telepathology tool works as an add-on to the company’s D2 desktop whole slide scanner, which enhances remote viewing and remote control of the device. Keith J. Kaplan, MD, surgical pathologist and producer of the Digital Pathology Blog, recently tested the Live-Q user experience in a café over a standard typical Wi-Fi connection. He wrote in his review, “In summary, this system works on every level. It’s fast, it’s responsive, it’s intuitive, it’s high quality, and it’s easy

Troponin I assay, 7/13:104

Beckman Coulter has received FDA 510(k) clearance for its Access AccuTnI+3 troponin I assay for use on its Access 2 immunoassay system. In accordance with FDA requirements, the company conducted a large multicenter prospective clinical trial on the AccuTnI+3 troponin I assay that enrolled more than 1,900 subjects, and confirmed that the assay provides the clinical performance necessary for optimal patient management. The data from this trial show that Beckman Coulter’s Access AccuTnI+3 troponin I assay provides the precision, clinical

Rabbit monoclonal antibodies portfolio, 7/13:104

Bio SB offers a portfolio of more than 130 rabbit monoclonal antibodies. “Rabbit monoclonal antibodies offer higher sensitivity and specificity when compared to mouse monoclonal antibodies traditionally used in laboratory applications,” Alfonso Heras, president and CEO of Bio SB, said in a statement. “Coupled with our new line of detection systems and chromogens, such as our PolyDetector HRP Plus, PolyDetector AP, and HRP Green, Bio SB can offer a large array of immunohistochemistry products to pathologists around the world.”

Hematology analyzer, 6/13:96

Beckman Coulter’s UniCel DxH 600 Coulter cellular analysis system is a benchtop hematology analyzer for mid- to high-volume laboratories. The system provides laboratories with exceptional quality results, improved first-pass accuracy, and automatic rerun and reflex testing, thereby reducing overall manual review rates and processes.

Next-generation lab automation solution

Abbott has launched its Accelerator a3600 next-generation automation solution, which helps laboratories process tests faster while handling increased volume. The Accelerator a3600 processes up to 3,600 samples per hour and handles multiple tube sizes and types simultaneously.

Multiplexing system with GI pathogen panel, 6/13:96

Luminex has received FDA clearance for its Magpix instrument with the xTAG gastrointestinal pathogen panel (xTAG GPP). This is the first clinical assay to be cleared on Magpix. xTAG GPP simultaneously detects 11 common viral, bacterial, and parasitic causes of infectious gastroenteritis from a single patient sample.

MARKETPLACE

TRENDING